RPRXHealthcare · BiotechnologyThe 8 Wall Street analysts covering Royalty Pharma plc hold a median 12-month price target of $65 — +10.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 86 of 100 as at 15 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Royalty Pharma plc on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (99): The share price has been relatively steady.
Issuance (33): The company has been issuing shares or taking on financing, diluting existing holders.
Size (7): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on RPRX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +10.9% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Aug 2026 | JP Morgan | Maintains | Overweight | $58 → $62 |
| 13 July 2026 | TD Cowen | Maintains | Buy | $50 → $65 |
| 13 July 2026 | TD Cowen | Maintains | Buy | — |
| 7 May 2026 | Citigroup | Maintains | Buy | — |
| 7 May 2026 | JP Morgan | Maintains | Overweight | — |
| 21 Apr 2026 | UBS | Maintains | Buy | — |
| 10 Apr 2026 | Morgan Stanley | Maintains | Overweight | — |
| 30 Jan 2026 | UBS | Upgrade | Buy | — |
| 27 Jan 2026 | Citigroup | Maintains | Buy | — |
| 11 Dec 2025 | TD Cowen | Maintains | Buy | — |
| 10 Oct 2025 | Morgan Stanley | Maintains | Overweight | — |
| 30 Sept 2025 | Goldman Sachs | Initiates | Buy | — |
| 22 July 2025 | Citigroup | Maintains | Buy | — |
| 10 July 2025 | Morgan Stanley | Maintains | Overweight | — |
| 25 Oct 2024 | Citigroup | Maintains | Buy | — |
| 14 Aug 2024 | Goldman Sachs | Maintains | Buy | — |
| 11 July 2024 | Morgan Stanley | Maintains | Overweight | — |
| 3 June 2024 | UBS | Downgrade | Neutral | — |
| 12 Apr 2024 | B of A Securities | Maintains | Buy | — |
| 20 Feb 2024 | Goldman Sachs | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RPRX appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 26% of US stocks
Cheaper than 12% of US stocks
Cheaper than 29% of US stocks
Cheaper than 13% of US stocks
Higher than 65% of US stocks
Higher than 11% of US stocks
Higher than 79% of US stocks
Higher than 91% of US stocks
Higher than 72% of US stocks
Higher than 77% of US stocks
Higher than 38% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Royalty Pharma plc — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Royalty Pharma (RPRX) has crossed above its 20-day moving average, a technical level Zacks identifies as a key level of support. This crossing points to a possible short-term bullish trend for the stock.
Why it matters — For RPRX watchers, a move above the 20-day moving average may signal improving short-term technical momentum worth monitoring.
Royalty Pharma announced an agreement to provide $100 million in funding to Zealand Pharma in exchange for Zealand Pharma's economics related to rusfertide (PTG-300), a potential first-in-class therapy for polycythemia vera, a rare and chronic blood disorder.
Why it matters — Royalty Pharma watchers would care because this expands the company's interest in a potential first-in-class therapy for a rare blood disorder through a new funding agreement.
Zealand Pharma has entered into a USD 100 million royalty purchase and sale agreement with Royalty Pharma, selling its economic interests in rusfertide, including royalty rights on potential future global net sales of the product.
Why it matters — The agreement expands Royalty Pharma's portfolio with rights to potential future royalties on rusfertide global net sales.
Royalty Pharma reported higher second-quarter royalty receipts, continued capital deployment, and progress across its development-stage pipeline. The company raised its 2026 outlook for the second consecutive quarter.
Why it matters — A raised 2026 outlook for a second straight quarter signals improving expectations for RPRX's royalty revenue and business momentum.
Royalty Pharma plc held its Q2 2026 earnings call, with a transcript of the call published by Seeking Alpha. The call covered the company's second-quarter financial results and management discussion.
Why it matters — A RPRX watcher would care because the earnings call transcript provides direct insight into the company's quarterly performance and management commentary.
The 8 Wall Street analysts covering Royalty Pharma plc have a median 12-month price target of $65, with estimates ranging from $61 to $70. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 8 analysts covering Royalty Pharma plc, 7 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Royalty Pharma plc 86 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 15 Aug 2026, Royalty Pharma plc ranks 86 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (99 of 100).
No one can know that. What the data says: the median 12-month target from 8 analysts implies +10.9% from the last close, and Ticker Nerd's factor model ranks Royalty Pharma plc 86 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Royalty Pharma plc publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RPRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $61 to $70 over the next 12 months.
Royalty Pharma plc returned +64.8% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Royalty Pharma plc is the world's largest buyer of biopharmaceutical royalties and a leading funder of innovation in the life sciences sector. The company acquires royalties entitling it to payments based on net sales of approved therapies and development-stage product candidates, partnering with innovators from academic institutions, research hospitals, nonprofits, small and mid-cap biotechnology firms, and major global pharmaceutical companies.
The most recent item we track (Zacks Investment Research, 13 Aug 2026): "Royalty Pharma (RPRX) Crossed Above the 20-Day Moving Average: What That Means for Investors". Royalty Pharma (RPRX) has crossed above its 20-day moving average, a technical level Zacks identifies as a key level of support. This crossing points to a possible short-term bullish trend for the stock.
Royalty Pharma plc is the world's largest buyer of biopharmaceutical royalties and a leading funder of innovation in the life sciences sector. The company acquires royalties entitling it to payments based on net sales of approved therapies and development-stage product candidates, partnering with innovators from academic institutions, research hospitals, nonprofits, small and mid-cap biotechnology firms, and major global pharmaceutical companies. Its extensive portfolio encompasses royalties on more than 35 commercial products addressing conditions such as cystic fibrosis (e.g., Vertex's Trikafta and Kalydeco), multiple sclerosis (e.g., Biogen's Tysabri and Spinraza), blood cancers (e.g., Imbruvica from AbbVie and Johnson & Johnson), prostate cancer (e.g., Xtandi from Astellas and Pfizer), ATTR amyloidosis (e.g., Alnylam's Amvuttra), and schizophrenia (e.g., Bristol Myers Squibb's Cobenfy), alongside over 20 pipeline assets targeting vitiligo, Hunter syndrome, lupus, hereditary angioedema, and cardiovascular disease. Royalty Pharma plc provides tailored non-dilutive funding solutions to support late-stage clinical trials and product launches, holding a dominant position with significant global market share in biopharma royalty transactions. Founded in 1996 and headquartered in New York, NY, it operates at the intersection of science, medicine, and investing to accelerate bio-innovation.
CEO Mr. Pablo Legorreta · 100 employees · United States · https://www.royaltypharma.com